Skip to main content
Erschienen in: DNP - Der Neurologe & Psychiater 1/2018

29.01.2018 | Parkinson-Krankheit | Fortbildung

Morbus Parkinson

Was leistet der neue COMT-Hemmer Opicapon?

verfasst von: Dr. rer. nat. Daniel Bomar, Prof. Dr. med. Wolfgang Jost

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die medikamentöse Therapie des Parkinson-Syndroms hat sich in den letzten Jahren deutlich verbessert. Obwohl eine kausale Behandlung bislang nicht möglich ist, zählt Morbus Parkinson heute zu den symptomatisch gut behandelbaren neurologischen Erkrankungen. Das liegt weniger an neuen Substanzklassen, als vielmehr an einer individualisierten Therapie, die verschiedene Faktoren wie Alter, Geschlecht, führende Symptomatik und Begleiterkrankungen umfasst.
Literatur
2.
Zurück zum Zitat Nutt JG et al. 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 1987; 21:584–8CrossRefPubMed Nutt JG et al. 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 1987; 21:584–8CrossRefPubMed
3.
Zurück zum Zitat Kiss LE et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2010; 53(8):3396–411CrossRefPubMed Kiss LE et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2010; 53(8):3396–411CrossRefPubMed
4.
Zurück zum Zitat Bonifácio MJ et al. Evaluation of potential mechanisms of cellular toxicity by nitrocatechol COMT inhibitors: opicapone, entacapone and tolcapone Presented at: XX. World Congress on Parkinson’s Disease and Related Disorders 2013, Geneva, Switzerland Bonifácio MJ et al. Evaluation of potential mechanisms of cellular toxicity by nitrocatechol COMT inhibitors: opicapone, entacapone and tolcapone Presented at: XX. World Congress on Parkinson’s Disease and Related Disorders 2013, Geneva, Switzerland
5.
Zurück zum Zitat Almeida L et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 2013; 52(2):139–51CrossRefPubMed Almeida L et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 2013; 52(2):139–51CrossRefPubMed
6.
Zurück zum Zitat Palma PN et al. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstrate relative free energy calculations. J Comput Chem 2012; 33(9):970–86CrossRefPubMed Palma PN et al. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstrate relative free energy calculations. J Comput Chem 2012; 33(9):970–86CrossRefPubMed
7.
Zurück zum Zitat Rocha JF et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol 2014 a; 70(3):279–86CrossRefPubMed Rocha JF et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol 2014 a; 70(3):279–86CrossRefPubMed
8.
Zurück zum Zitat Rocha JF et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014 b; 70(9):1059–71CrossRefPubMed Rocha JF et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014 b; 70(9):1059–71CrossRefPubMed
9.
Zurück zum Zitat Rocha JF et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 2013; 76(5):763–75CrossRefPubMedPubMedCentral Rocha JF et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 2013; 76(5):763–75CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ferreira JJ et al. Pooled efficacy analysis of opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations. Poster presented at the 1stCongress of the European Academy of Neurology, Berlin, June 20-23, 2015c Ferreira JJ et al. Pooled efficacy analysis of opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations. Poster presented at the 1stCongress of the European Academy of Neurology, Berlin, June 20-23, 2015c
11.
Zurück zum Zitat Costa R et al. One-year open-label efficacy and safety of opicapone in Parkinson’s disease BIPARK-II study. Mov Disord 2014; 29(suppl 1):S233 Costa R et al. One-year open-label efficacy and safety of opicapone in Parkinson’s disease BIPARK-II study. Mov Disord 2014; 29(suppl 1):S233
12.
Zurück zum Zitat Ferreira JJ et al. Switching double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I. Mov Disord 2016 b; 31(suppl 2):S633 Ferreira JJ et al. Switching double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I. Mov Disord 2016 b; 31(suppl 2):S633
13.
Zurück zum Zitat Oliviera C et al. Opicapone and non-motor symptoms in Parkinson’s disease: results from double-blind, randomized, placebo-controlled study and open-label extension. Mov Disord 2015; 30(Suppl 1):S173 Oliviera C et al. Opicapone and non-motor symptoms in Parkinson’s disease: results from double-blind, randomized, placebo-controlled study and open-label extension. Mov Disord 2015; 30(Suppl 1):S173
14.
Zurück zum Zitat Lees A et al. Efficacy and safety of opicapone in patients over 70 years with Parkinson’s disease and motor fluctuations. Mov Disord 2015; 30(suppl 1):S99 Lees A et al. Efficacy and safety of opicapone in patients over 70 years with Parkinson’s disease and motor fluctuations. Mov Disord 2015; 30(suppl 1):S99
15.
Zurück zum Zitat Rocha JF et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev 2016; 5(3):232–40CrossRefPubMed Rocha JF et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev 2016; 5(3):232–40CrossRefPubMed
16.
Zurück zum Zitat Ferreira JJ et al. Effect of opicapone on levodopa pharmakokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol 2015; 22(5):815–25CrossRefPubMed Ferreira JJ et al. Effect of opicapone on levodopa pharmakokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol 2015; 22(5):815–25CrossRefPubMed
17.
Zurück zum Zitat Ferreira JJ et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 2016; 15(2):154–65CrossRefPubMed Ferreira JJ et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 2016; 15(2):154–65CrossRefPubMed
18.
Zurück zum Zitat Lees A et al. Efficacy and safety of opicapone, a new COMT-inhibitor for the treatment of motor fluctuations in Parkinson’s disease patients: BIPARK-II-study (abstract no. 1038) J Neurol Sci 2013; 333(suppl 1): e116CrossRef Lees A et al. Efficacy and safety of opicapone, a new COMT-inhibitor for the treatment of motor fluctuations in Parkinson’s disease patients: BIPARK-II-study (abstract no. 1038) J Neurol Sci 2013; 333(suppl 1): e116CrossRef
19.
Zurück zum Zitat Annus A, Vécsei L. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy. Drug Des Devel Ther 2017; 11:143–51CrossRefPubMedPubMedCentral Annus A, Vécsei L. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy. Drug Des Devel Ther 2017; 11:143–51CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Lopes N et al. Hepatic safety of opicapone in Parkinson’s disease patients. Mov Disord 2015 b; 30(suppl. 1):101 Lopes N et al. Hepatic safety of opicapone in Parkinson’s disease patients. Mov Disord 2015 b; 30(suppl. 1):101
21.
Zurück zum Zitat Lopes N et al. Exploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s disease. Mov Disord 2015; 30(suppl. 1):101 Lopes N et al. Exploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s disease. Mov Disord 2015; 30(suppl. 1):101
22.
Zurück zum Zitat Lees AJ et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: A randomized clinical trial. JAMA Neurol 2017; 74:197–206CrossRefPubMed Lees AJ et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: A randomized clinical trial. JAMA Neurol 2017; 74:197–206CrossRefPubMed
23.
Zurück zum Zitat Lopes N et al. Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression. Mov Disord 2016; 31(suppl. 2):642 Lopes N et al. Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression. Mov Disord 2016; 31(suppl. 2):642
24.
Zurück zum Zitat Ferreira J et al. Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease treated with opicapone. Mov Disord 2016 c; 31(suppl 2):S643 Ferreira J et al. Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease treated with opicapone. Mov Disord 2016 c; 31(suppl 2):S643
25.
Zurück zum Zitat Santos A et al. Safety of opicapone in fluctuating Parkinson’s disease patients: results of the 1-year extension of study BIPARK I. Mov Disord 2016; 31(suppl. 2):641 Santos A et al. Safety of opicapone in fluctuating Parkinson’s disease patients: results of the 1-year extension of study BIPARK I. Mov Disord 2016; 31(suppl. 2):641
26.
Zurück zum Zitat Lees A et al. 1-year-safety of opicapone in patients with Parkinson’s disease and motor fluctuations. Mov Disord 2015 b; 30(suppl 1): S99 Lees A et al. 1-year-safety of opicapone in patients with Parkinson’s disease and motor fluctuations. Mov Disord 2015 b; 30(suppl 1): S99
27.
Zurück zum Zitat Lopes N et al. Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment. Mov Disord 2016 b; 31(suppl. 2):643 Lopes N et al. Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment. Mov Disord 2016 b; 31(suppl. 2):643
28.
Zurück zum Zitat Pinto R et al. Cardiac safety of opicapone in patients with Parkinson’s disease: analysis of the centralized phase III ECG dataset. Mov Disord 2015; 30(suppl. 1):112 Pinto R et al. Cardiac safety of opicapone in patients with Parkinson’s disease: analysis of the centralized phase III ECG dataset. Mov Disord 2015; 30(suppl. 1):112
Metadaten
Titel
Morbus Parkinson
Was leistet der neue COMT-Hemmer Opicapon?
verfasst von
Dr. rer. nat. Daniel Bomar
Prof. Dr. med. Wolfgang Jost
Publikationsdatum
29.01.2018
Verlag
Springer Medizin
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 1/2018
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-018-1912-y

Weitere Artikel der Ausgabe 1/2018

DNP - Der Neurologe & Psychiater 1/2018 Zur Ausgabe

Medizin aktuell

Das beste Cover 2017

Industrieforum

Neues MS-Generikum